Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Placebo Controlled, Double Blind, Multicentre Proof of Concept Study to Assess the Safety and Efficacy of Two Doses of VAD044 in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

NCT05406362 is registered in ClinicalTrials.gov with Vaderis Therapeutics AG as lead sponsor.

NCT NCT05406362
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05406362 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Placebo Controlled, Double Blind, Multicentre Proof of Concept Study to Assess the Safety and Efficacy of Two Doses of VAD044 in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
Lead sponsor
Vaderis Therapeutics AG
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
July 18, 2022
Completion date
January 31, 2027
Enrollment
75 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary hemorrhagic telangiectasia (hht)